vs
Side-by-side financial comparison of AVALON HOLDINGS CORP (AWX) and NewAmsterdam Pharma Co N.V. (NAMS). Click either name above to swap in a different company.
AVALON HOLDINGS CORP is the larger business by last-quarter revenue ($21.5M vs $19.1M, roughly 1.1× NewAmsterdam Pharma Co N.V.). AVALON HOLDINGS CORP runs the higher net margin — -1.7% vs -90.7%, a 89.0% gap on every dollar of revenue. On growth, NewAmsterdam Pharma Co N.V. posted the faster year-over-year revenue change (740.1% vs 21.7%). AVALON HOLDINGS CORP produced more free cash flow last quarter ($-166.0K vs $-37.8M).
Avalon Hill Games Inc. is a game company that publishes wargames and strategic board games. It has also published miniature wargaming rules, role-playing games and sports simulations. It is a subsidiary of Hasbro, and operates under the company's "Hasbro Gaming" division.
Kite Pharma, Inc. is an American biotechnology company that develops cancer immunotherapy products with a primary focus on genetically engineered autologous CAR T cell therapy - a cell-based therapy which relies on chimeric antigen receptors and T cells. Founded in 2009, and based in Santa Monica, California, it was acquired by Gilead Sciences in 2017.
AWX vs NAMS — Head-to-Head
Income Statement — Q4 FY2025 vs Q2 FY2025
| Metric | | |
|---|---|---|
| Revenue | $21.5M | $19.1M |
| Net Profit | $-356.0K | $-17.4M |
| Gross Margin | 17.1% | — |
| Operating Margin | 0.4% | -186.1% |
| Net Margin | -1.7% | -90.7% |
| Revenue YoY | 21.7% | 740.1% |
| Net Profit YoY | 28.4% | 55.5% |
| EPS (diluted) | — | $-0.15 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $21.5M | — | ||
| Q3 25 | $25.7M | — | ||
| Q2 25 | $20.3M | $19.1M | ||
| Q1 25 | $16.1M | — | ||
| Q4 24 | $17.6M | $12.8M | ||
| Q3 24 | $24.2M | $29.1M | ||
| Q2 24 | $23.1M | — | ||
| Q1 24 | $18.9M | — |
| Q4 25 | $-356.0K | — | ||
| Q3 25 | $1.9M | — | ||
| Q2 25 | $274.0K | $-17.4M | ||
| Q1 25 | $-1.5M | — | ||
| Q4 24 | $-497.0K | $-92.2M | ||
| Q3 24 | $1.8M | $-16.6M | ||
| Q2 24 | $954.0K | — | ||
| Q1 24 | $-979.0K | — |
| Q4 25 | 17.1% | — | ||
| Q3 25 | 23.7% | — | ||
| Q2 25 | 20.6% | — | ||
| Q1 25 | 14.8% | — | ||
| Q4 24 | 17.5% | — | ||
| Q3 24 | 24.6% | — | ||
| Q2 24 | 22.1% | — | ||
| Q1 24 | 16.2% | — |
| Q4 25 | 0.4% | — | ||
| Q3 25 | 9.1% | — | ||
| Q2 25 | 3.7% | -186.1% | ||
| Q1 25 | -7.2% | — | ||
| Q4 24 | -0.8% | -338.5% | ||
| Q3 24 | 9.4% | -85.9% | ||
| Q2 24 | 6.3% | — | ||
| Q1 24 | -2.7% | — |
| Q4 25 | -1.7% | — | ||
| Q3 25 | 7.4% | — | ||
| Q2 25 | 1.4% | -90.7% | ||
| Q1 25 | -9.3% | — | ||
| Q4 24 | -2.8% | -721.7% | ||
| Q3 24 | 7.6% | -57.2% | ||
| Q2 24 | 4.1% | — | ||
| Q1 24 | -5.2% | — |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | $-0.15 | ||
| Q1 25 | — | — | ||
| Q4 24 | — | $-0.91 | ||
| Q3 24 | — | $-0.18 | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $4.1M | $739.2M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $38.4M | $778.5M |
| Total Assets | $87.4M | $815.1M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $4.1M | — | ||
| Q3 25 | $4.6M | — | ||
| Q2 25 | $3.7M | $739.2M | ||
| Q1 25 | $1.3M | — | ||
| Q4 24 | $2.8M | $834.2M | ||
| Q3 24 | $3.9M | $422.7M | ||
| Q2 24 | $3.8M | — | ||
| Q1 24 | $1.2M | — |
| Q4 25 | $38.4M | — | ||
| Q3 25 | $38.7M | — | ||
| Q2 25 | $36.8M | $778.5M | ||
| Q1 25 | $36.5M | — | ||
| Q4 24 | $38.0M | $757.5M | ||
| Q3 24 | $38.5M | $378.9M | ||
| Q2 24 | $36.7M | — | ||
| Q1 24 | $35.7M | — |
| Q4 25 | $87.4M | — | ||
| Q3 25 | $90.7M | — | ||
| Q2 25 | $88.1M | $815.1M | ||
| Q1 25 | $87.6M | — | ||
| Q4 24 | $86.2M | $864.6M | ||
| Q3 24 | $89.1M | $439.2M | ||
| Q2 24 | $91.7M | — | ||
| Q1 24 | $90.6M | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $278.0K | $-37.7M |
| Free Cash FlowOCF − Capex | $-166.0K | $-37.8M |
| FCF MarginFCF / Revenue | -0.8% | -197.2% |
| Capex IntensityCapex / Revenue | 2.1% | 0.5% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $2.1M | $-119.7M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $278.0K | — | ||
| Q3 25 | $1.5M | — | ||
| Q2 25 | $3.0M | $-37.7M | ||
| Q1 25 | $-982.0K | — | ||
| Q4 24 | $-579.0K | $-37.5M | ||
| Q3 24 | $342.0K | $-12.5M | ||
| Q2 24 | $3.2M | — | ||
| Q1 24 | $411.0K | — |
| Q4 25 | $-166.0K | — | ||
| Q3 25 | $852.0K | — | ||
| Q2 25 | $2.7M | $-37.8M | ||
| Q1 25 | $-1.4M | — | ||
| Q4 24 | $-1.1M | $-37.5M | ||
| Q3 24 | $-660.0K | $-12.6M | ||
| Q2 24 | $2.9M | — | ||
| Q1 24 | $56.0K | — |
| Q4 25 | -0.8% | — | ||
| Q3 25 | 3.3% | — | ||
| Q2 25 | 13.5% | -197.2% | ||
| Q1 25 | -8.5% | — | ||
| Q4 24 | -6.4% | -293.5% | ||
| Q3 24 | -2.7% | -43.2% | ||
| Q2 24 | 12.4% | — | ||
| Q1 24 | 0.3% | — |
| Q4 25 | 2.1% | — | ||
| Q3 25 | 2.3% | — | ||
| Q2 25 | 1.4% | 0.5% | ||
| Q1 25 | 2.4% | — | ||
| Q4 24 | 3.1% | 0.0% | ||
| Q3 24 | 4.1% | 0.3% | ||
| Q2 24 | 1.5% | — | ||
| Q1 24 | 1.9% | — |
| Q4 25 | — | — | ||
| Q3 25 | 0.76× | — | ||
| Q2 25 | 11.07× | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 0.19× | — | ||
| Q2 24 | 3.35× | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
